Highly Anticipated Amflow PL Carbon and PL Carbon Pro Hit the US Market
LOS ANGELES, July 30, 2025 /PRNewswire/ -- Amflow, the first brand equipped with the Avinox eDrive System, announces the availability of the Amflow PL Carbon and PL Carbon Pro in the United States starting today, July 30, 2025.
A year after its hugely successful launch at Eurobike 2024, the bike became available first in Germany, Australia, and the United Kingdom, followed by Spain, France, Italy, and Belgium in early 2025. Since its global debut, the bike has received the gold winner of "EMTB of the Year" by EMTB-News.de and Design and Innovation Award 2025, and its groundbreaking Avinox e-bike system has been awarded the "Most Innovation Brand" by EMTB-News.de, Design and Innovation Award 2025, the "Best in Test" Award by E-MOUNTAINBIKE Magazine, and Singletrack World Magazine's "Standout Product of the Year 2024", among other accolades.
Model
Amflow PL Carbon
Amflow PL Carbon Pro
Frame
Amflow PL Carbon Frame
Satin Silver
150mm rear travel
Compatible with 27.5" and 29" rear wheels
Amflow PL Carbon Frame
Cosmic Black
150mm rear travel
Compatible with 27.5" and 29" rear wheels
E-Bike Drive System
Motor: Avinox M1 Drive Unit: 105 Nm
Control System:
Avinox Screen: 2-inch built-in OLED Control Display, barometer, compass, ambient light sensor, torque/cadence/wheel speed sensors
Avinox Wireless Controllers: Right and left sides
Charger: Avinox Fast Charger: 12A/508W
Battery: Avinox Integrated Battery: 800Wh
Suspension
Fork: 2026 FOX 36 Performance,
160mm travel, GRIP Damper
Rear Shock: 2026FOX Float Performance,
Trunnion (185×55mm)
Fork: 2026 FOX 36 Factory, 160mm travel, GRIP X2 Damper
Rear Shock: 2026FOX FLOAT X Factory,
Trunnion（185×55mm)
Transmission
SRAM Eagle 70 Transmission
SRAM XO Eagle Transmission
Brakes
Magura MT5 hydraulic disc brake
Magura MT7 Pro hydraulic disc brake
Wheels
Amflow HMA-30, Alloy, 29"
Amflow HMC-30, Carbon, 29"
Tires
Front: Maxxis Assegai MaxxTerra 29×2.5"
WT 3C EXO E-25 TLR
Rear: Maxxis DissectorMaxxTerra 29×2.4"
WT 3C EXO+ E-25 TLR
Front: Maxxis Assegai MaxxTerra 29×2.5"
WT 3C EXO E-25 TLR
Rear: Maxxis DissectorMaxxTerra 29×2.4"
WT 3C EXO+ E-25 TLR
Full specs available at https://www.amflowbikes.com/pl-carbon/specs
Ultra-light Frame, Organic Design
The Amflow PL is a full-power eMTB with a stunningly lightweight body. The ultra-light carbon fiber frame weighs just 2.27kg1 and has been designed and expertly-crafted to deliver the ultimate ride, wherever the rider is headed.
Tackle Terrain with Confidence
At the heart of the Amflow PL is the Avinox Drive System incorporating multiple cutting-edge technologies in both software and hardware design. The motor provides an industry-leading power-to-size ratio, with 105 Nm torque.
Preference Matching Assistance
In addition to traditional assistance modes, the Avinox Drive System also features a specialized Auto mode, which adapts assistance in real-time based on road conditions and riding position1. Once enabled, Auto mode empowers users to tackle a wide variety of terrain types and gradients without having to switch modes.
For the most challenging trails, Boost mode can be activated to instantly receive 120 Nm of torque, enabling steep inclines to be tackled with ease.
Furthermore, Amflow PL has Walk mode which features intelligent walk assistance for easy incline traversing, Auto Hold to prevent rollback on slopes, and Hill Start Assist for additional torque to get riders started on inclines. It also allows stationary gear-shifting for a smooth and intuitive experience.
Fast Charging, High-Capacity Battery Offers Extended Range
The Avinox system's battery weighs just 2.87kg1 and boasts an ultra-high energy density, ensuring an uncompromised range.
For those wanting to get back out there as soon as possible, a compact and convenient fast charger1 is capable of charging the battery from 0% to 75% in just 1.5 hours1.
Real-time monitoring, self-discharge, active voltage reduction, and abnormality alerts all feed into the battery health management system to create a durable and reliable battery that still maintains at least 80% capacity after 500 charge-discharge cycles1.
Agile and Responsive with Cutting-edge Geometry
The Amflow PL's all-around frame design features cutting-edge geometry, offering balanced performance that's both lightweight and hyper-agile, empowering riders to easily take on rugged trails and more technical rides.
For those looking to adapt the wheel size to their needs, the Amflow PL frame structure is compatible with both 27.5" and 29" rear wheels1. So, whether looking for a smoother ride with larger wheels or agility with smaller ones, a simple adjustment of the flip chip will allow for either size to be fitted without altering the frame's geometric center of gravity.
Optimized Ride Efficiency
Featuring a four-bar linkage structure, the Amflow PL significantly reduces pedal kickback while greatly improving pedaling efficiency, ensuring that every pedal stroke counts.
Superior Suspension
The rear shock, co-tuned with FOX, offers a sensitive initial stroke response to effectively filter out minor vibrations. It also provides powerful end-stroke support to prevent bottom-outs during continuous high-speed impacts or steep descents, enabling riders to fully enjoy every off-road adventure.
Control at Your Fingertips
At the core of the Avinox system is a 2" full-color OLED touchscreen control display which is integrated directly into the frame of the Amflow PL. Riders are presented with a wealth of information including real-time riding data, estimated range and the ability to adjust the setup with just a swipe.
Even greater control can be gained by Bluetooth-enabled Wireless Controllers that connect wirelessly to the control display. Mode switches can be made while riding.
When connected to the Avinox App riders have access to:
Customizable Parameters: Parameters of riding modes can be quickly customized to adjust power, torque and cadence, according to riding habits.
Anti-theft Mode1: A password-protected anti-theft mode will sound an alarm and the app will send a notification, if unauthorized movement of the eMTB is detected.
Remote Locating: The bike's real-time location can easily be checked.
Comprehensive Data Recording, Easy Metric Sharing
With the control display or the Avinox app, riders can review rich data like speeds, range, cadence, power, torque, gradient, altitude, calories burned, ride times, heart rate, and more. This data can also be easily synced with third-party apps such as Strava to share with friends and the eMTB community.
Price and Availability
Amflow PL Carbon Pro (800Wh) and the Amflow PL Carbon (800Wh), are available today and are priced at $10,199 USD and $7,499 USD respectively. They can be purchased from Amflow official store and official local authorized dealers listed here: https://www.amflowbikes.com/test-ride
For more information about Amflow and Amflow PL, please visit: https://www.amflowbikes.com/pl-carbon
1 All data was tested in controlled conditions. Actual experience may vary. For more details, please refer to the product page on the official Amflow website.
About AmflowProudly born in 2023, Amflow is the creation of tech experts with a limitless passion for riding mountain bikes. The company strives to amaze with an unmatched combination of power, range, and performance, hidden in sleek electric mountain bike bodies. Amflow's commitment to the e-bike industry is to make its e-mountain bikes the go-to for all e-bike riders looking to turn any terrain into a wonderland of possibilities.
For more information, visit our: Website: https://www.amflowbikes.comFacebook: https://www.facebook.com/amflowbikes/Instagram: https://www.instagram.com/amflowbikesTiktok: https://www.tiktok.com/@amflowbikesSubscribe to our YouTube Channel: https://www.youtube.com/@amflowbikes
View original content to download multimedia:https://www.prnewswire.com/news-releases/highly-anticipated-amflow-pl-carbon-and-pl-carbon-pro-hit-the-us-market-302517055.html
SOURCE Amflow
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
19 minutes ago
- Bloomberg
PG&E Falls on Newsom Plan for Investors Payment into Fire Fund
PG&E Corp. shares fell on a proposal by California Governor Gavin Newsom that would require the utility company's shareholders to make a significant contribution to the replenishment of California's wildfire insurance fund. PG&E dropped as much as 5% Thursday morning after the Newsom's plan was reported by Bloomberg News a day earlier. PG&E declined to comment on the report.
Yahoo
39 minutes ago
- Yahoo
123Invent Inventor Develops Smart Panel Garage Door (BDH-321)
PITTSBURGH, July 31, 2025 /PRNewswire/ -- "I thought there should be a way to make a garage door more functional by additional various options such as ventilation fans, heating/cooling modulars, or solar panels," said an inventor,from Washington, D.C., "so I invented the SMART PANEL GARAGE DOOR. My design also enables you to change the appearance of the garage door for added style." The invention provides a modular smart panel garage door. In doing so, it would dramatically increase the functional utility of a garage door. As a result, it enables the owner to utilize heating, ventilation, air conditioning, television, etc. It also could enhance the appearance of the garage door. The invention features an innovative design that is easy to install and use so it is ideal for residential and commercial building applications. The SMART PANEL GARAGE DOOR is currently available for licensing or sale to manufacturers or marketers. For more information, visit Or contact Nicholas Lee at 202-352-1532 or email info@ View original content to download multimedia: SOURCE InventHelp Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Glaucoma Treatment Devices Market Set to Surge from USD 4.5 Billion in 2024 to USD 7.2 Billion by 2033, Driven by Advancements in Minimally Invasive Surgical Technologies: Market Research Intellect
The growth of the Glaucoma Treatment Devices Market is primarily driven by the rising global prevalence of glaucoma, increasing awareness about early diagnosis, and advancements in minimally invasive treatment options. Technological innovations in surgical devices, coupled with supportive government initiatives and healthcare infrastructure improvements, are expected to accelerate adoption and significantly contribute to the market's steady growth over the forecast period. LEWES, Del., July 31, 2025 /PRNewswire/ -- The Glaucoma Treatment Devices Market was valued at approximately USD 4.5 billion in 2024 and is projected to reach USD 7.2 billion by 2033, reflecting a robust compound annual growth rate (CAGR) of 6.5% from 2026 to 2033. This growth is attributed to the rising burden of glaucoma worldwide, increasing adoption of advanced surgical interventions, and improved accessibility to ophthalmic care. Expanding healthcare infrastructure and ongoing innovation in treatment technologies are further enhancing market size and investment potential. Key Highlights of the Report: The global Glaucoma Treatment Devices Market reached USD 4.5 billion in 2024 and is anticipated to grow to USD 7.2 billion by 2033, at a CAGR of 6.5% from 2026 to 2033. Technological advancements in minimally invasive glaucoma surgery (MIGS) devices are accelerating adoption across hospitals and specialty clinics. Aging populations and increasing glaucoma diagnoses are significantly boosting demand for long-term treatment solutions. North America continues to dominate the market, while Asia-Pacific is projected to witness the fastest growth due to rising healthcare investment. Leading market players are focusing on product innovation, strategic partnerships, and geographic expansion to strengthen their global footprint. Why This Report Matters: This report offers a comprehensive analysis of the Glaucoma Treatment Devices Market, delivering valuable insights into market size, growth trends, and key drivers shaping the industry through 2033. It equips stakeholders, investors, and healthcare professionals with data-driven intelligence to make informed decisions. By examining regional dynamics, competitive strategies, and technological advancements, the report highlights growth opportunities and emerging risks. Whether for market entry or expansion planning, this research provides critical knowledge to navigate a rapidly evolving ophthalmic device landscape. Who Should Read This Report: Medical Device Manufacturers: To identify innovation trends and growth areas in glaucoma treatment technologies. Healthcare Providers & Ophthalmologists: To understand device adoption trends and treatment advancements. Hospital Procurement Teams: To evaluate top-performing products and make strategic purchasing decisions. Investors & Analysts: To assess market opportunities, ROI potential, and emerging investment segments. Pharmaceutical & Biotech Firms: To explore partnerships and product development aligned with surgical treatments. Regulatory Bodies & Policymakers: To track industry developments and ensure compliance with evolving standards. For more information or to purchase the report, please contact us at: Browse in-depth TOC on "Global Glaucoma Treatment Devices Market Size" 202 - Pages126 – Tables37 – Figures Global Glaucoma Treatment Devices Market Overview Market Driver 1. Rising Prevalence of Glaucoma Globally The global rise in aging populations has significantly contributed to the increase in glaucoma cases, especially in regions such as North America, Europe, and Asia-Pacific. Glaucoma remains a leading cause of irreversible blindness, and the growing awareness campaigns are facilitating early diagnosis and treatment. Primary open-angle glaucoma and angle-closure glaucoma are among the most prevalent types, driving higher demand for surgical intervention devices. Emerging economies are showing rapid uptake of eye health services due to improving healthcare infrastructure and government initiatives. Public health organizations and non-profits are working towards large-scale screening and education programs to reduce disease burden. 2. Technological Advancements in Glaucoma Devices Innovations in minimally invasive glaucoma surgery (MIGS) devices are transforming patient outcomes and reducing recovery times. Smart implantable devices capable of monitoring intraocular pressure (IOP) in real time are gaining clinical interest. Advancements in laser-based procedures and micro-stent technologies offer less invasive and more effective alternatives to traditional surgeries. The integration of AI and IoT with ophthalmic devices is expected to further revolutionize glaucoma management. Research and development investment from leading players continues to push the boundaries of device precision and safety. 3. Increasing Demand for Minimally Invasive Surgery (MIGS) MIGS procedures offer quicker recovery, fewer complications, and long-term management solutions for mild to moderate glaucoma. Hospitals and eye clinics are adopting MIGS as a frontline treatment, especially in patients unresponsive to medication. Surgeons prefer MIGS due to the reduced learning curve and increased safety profile compared to traditional surgeries. The growing body of clinical evidence supporting the efficacy of MIGS is accelerating its adoption globally. Medical device companies are focusing on developing next-generation MIGS implants tailored to patient-specific anatomical needs. To Purchase a Comprehensive Report Analysis: Market Restraint 1. High Cost and Limited Reimbursement Advanced glaucoma treatment devices, especially MIGS and smart implants, are often expensive and unaffordable for many patients. In low- and middle-income regions, lack of insurance coverage and weak reimbursement structures make access more difficult. Hospitals may be hesitant to invest in high-cost surgical equipment without clear financial incentives or ROI. Cost-related barriers discourage widespread adoption, even in regions where clinical need is high. 2. Regulatory and Operational Barriers Varying global regulatory standards can delay the introduction of new glaucoma devices into certain markets. Approval processes can be lengthy and costly, impacting smaller device manufacturers disproportionately. A shortage of trained ophthalmic surgeons familiar with advanced techniques limits the practical use of new devices. Operational challenges like poor device availability and long procurement cycles hinder adoption in developing areas. 3. Low Awareness and Poor Patient Compliance Lack of public knowledge about glaucoma symptoms and risks leads to delayed diagnosis and missed treatment windows. In rural or underserved regions, patients often lack access to routine eye exams or follow-up care. Even after surgery, poor adherence to post-operative monitoring and care reduces long-term treatment success. Educational and awareness gaps limit both prevention and management, especially in high-risk demographics. Geographical Dominance: North America holds a dominant position in the Glaucoma Treatment Devices Market, driven by advanced healthcare infrastructure, high awareness levels, and strong adoption of minimally invasive surgical technologies. The region benefits from a robust network of ophthalmic specialists and early access to regulatory-approved innovations. Meanwhile, Europe follows closely, supported by favorable reimbursement frameworks and a growing elderly population. Asia-Pacific is projected to experience the fastest growth due to rising glaucoma prevalence, expanding healthcare access, and increased investment in ophthalmic care across countries like China, India, and Japan. Key Players Leading companies are actively shaping the future of the Glaucoma Treatment Devices Market through innovation, strategic expansion, and product development. Key players include Alcon Inc., Glaukos Corporation, Ivantis Inc. (a part of Alcon), New World Medical, Santen Pharmaceutical Co., Ltd., Johnson & Johnson Vision, Ellex Medical Lasers Ltd., AqueSys Inc., Lumenis Ltd., and Sight Sciences, Inc. Glaucoma Treatment Devices Market Segment Analysis Based on the research, Market Research Intellect has segmented the global market into Technology, Application, Component and Geography. Glaucoma Treatment Devices Market by Device Type Diagnostic Devices Surgical Devices Therapeutic Devices Monitoring Devices Glaucoma Treatment Devices Market by End User Hospitals Eye Clinics Home Care Settings Research Institutions Glaucoma Treatment Devices Market, by Product Type Intraocular Pressure (IOP) Lowering Devices Laser Treatment Devices Drainage Devices Ocular Implants Glaucoma Treatment Devices Market, by Geography North America U.S Canada Mexico Europe Germany France U.K Rest of Europe Asia Pacific China Japan India Rest of Asia Pacific ROW Middle East & Africa Latin America Browse Related Reports: Open Angle Glaucoma Therapeutics Market is categorized based on Drug Type (Prostaglandin Analogs, Beta-Blockers, Alpha Agonists, Carbonic Anhydrase Inhibitors, Rho Kinase Inhibitors) and Route of Administration (Oral, Topical, Injectable) and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Patient Type (Adult, Pediatric) and Formulation (Liquid, Tablet, Sustained Release) and geographical regions Anti Glaucoma Eyedrops Market is categorized based on Prostaglandin Analogues (Latanoprost, Bimatoprost, Travoprost, Unoprostone, Tafluprost) and Beta Blockers (Timolol, Betaxolol, Carteolol, Levobunolol, Metipranolol) and Alpha Agonists (Brimonidine, Apraclonidine, Dipivefrin, Clonidine, Oxymetazoline) and Carbonic Anhydrase Inhibitors (Dorzolamide, Brinzolamide, Acetazolamide, Methazolamide, Brominidine) and Rho Kinase Inhibitors (Netarsudil, Ripasudil, Y-27632, AR-13324, K-115) and geographical regions Glaucoma Medications Market is categorized based on Medication Type (Prostaglandin Analogs, Beta Blockers, Alpha Agonists, Carbonic Anhydrase Inhibitors, Rho Kinase Inhibitors) and Formulation Type (Eye Drops, Oral Medications, Surgical Treatments, Laser Treatments, Implants) and Administration Route (Topical, Systemic, Intravitreal, Surgical, Ocular Insert) and geographical regions Glaucoma Pharmaceutical Market is categorized based on Therapeutic Class (Prostaglandin Analogues, Beta Blockers, Alpha Agonists, Carbonic Anhydrase Inhibitors, Rho Kinase Inhibitors) and Drug Formulation (Topical, Oral, Injectable, Sustained-release, Combination Therapy) and Route of Administration (Ophthalmic, Systemic, Intravitreal, Subconjunctival, Transdermal) and geographical regions About Us: Market Research Intellect Welcome to Market Research Intellect, where we lead the way in global research and consulting, proudly serving over 5,000 esteemed clients worldwide. Our mission is to empower your business with cutting-edge analytical research solutions, delivering comprehensive, information-rich studies that are pivotal for strategic growth and critical revenue decisions. Unmatched Expertise: Our formidable team of 250 highly skilled analysts and subject matter experts (SMEs) is the backbone of our operations. With extensive training in advanced data collection and governance, we delve into over 25,000 high-impact and niche markets. Our experts seamlessly integrate modern data collection techniques, robust research methodologies, and collective industry experience o produce precise, insightful, and actionable research. Diverse Industry Coverage: We cater to a wide array of industries, ensuring that our insights are both relevant and specialized. Our expertise spans: Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverages Having collaborated with numerous Fortune 2000 companies, we bring unparalleled experience and reliability to meet all your research needs. Our proven track record reflects our commitment to excellence and client satisfaction. Contact Us: Mr. Edwyne FernandesMarket Research IntellectCall Us on: +1 743 222 5439Email: sales@ Logo: View original content: SOURCE Market Research Intellect Sign in to access your portfolio
